Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Lisata Therapeutics ( (LSTA) ).
On June 10, 2025, Lisata Therapeutics, Inc. announced amendments to employment and separation agreements for key executives, including CEO David Mazzo, VP Kristen Buck, and senior officers James Nisco and Tariq Imam. These amendments include salary adjustments, changes to COBRA benefits, and clarifications on severance payments and conditions under Change in Control scenarios, aiming to align with regulatory compliance and provide clarity on executive compensation and benefits.
The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Average Trading Volume: 12,389
Technical Sentiment Signal: Sell
Current Market Cap: $21.15M
See more data about LSTA stock on TipRanks’ Stock Analysis page.